Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O43819

UPID:
SCO2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O43819; Q3T1B5; Q9UK87

BACKGROUND:
Protein SCO2 homolog, mitochondrial, is essential for energy production in cells, facilitating the transport of copper to cytochrome c oxidase subunit II and ensuring its proper function. It also regulates the redox state of cysteines in SCO1 during the maturation of the mitochondrial respiratory chain component.

THERAPEUTIC SIGNIFICANCE:
Given its association with diseases such as Mitochondrial complex IV deficiency, nuclear type 2, and Myopia 6, targeting Protein SCO2 homolog offers a promising avenue for therapeutic intervention. Its critical role in mitochondrial bioenergetics highlights its potential as a therapeutic target for mitochondrial disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.